GLP1R and Hypoglycemia: The DPP-4 inhibitors have neutral effects on body weight or risk of hypoglycemia (justified by the glucose-dependent insulin secretion mode of action of GLP-1) [62,92], except when there is concomitant treatment with insulin or sulfonylureas [93].